

Development of a TLR7/8 agonist adjuvant formulation to overcome early life hyporesponsiveness to DTaP vaccination

David Dowling

Precision Vaccines Program, Division of Infectious Diseases, Boston Children's Hospital, Boston, MA, USA <https://orcid.org/0000-0003-1095-6156>

Soumik Barman

Precision Vaccines Program, Division of Infectious Diseases, Boston Children's Hospital, Boston, MA, USA <https://orcid.org/0000-0002-3641-2125>

Alyson J. Smith

Center for Translational Medicine, University of Montana, Missoula, MT, USA

Francesco Borriello

Precision Vaccines Program, Division of Infectious Diseases, Boston Children's Hospital, Boston, MA, USA

Danielle Chaney

Precision Vaccines Program, Division of Infectious Diseases, Boston Children's Hospital, Boston, MA, USA

Spencer E. Brightman

Precision Vaccines Program, Division of Infectious Diseases, Boston Children's Hospital, Boston, MA, USA

Gandolina Malhem

Precision Vaccines Program, Division of Infectious Diseases, Boston Children's Hospital, Boston, MA, USA

Byron Brook

Precision Vaccines Program, Division of Infectious Diseases, Boston Children's Hospital, Boston, MA, USA

Manisha Menon

Precision Vaccines Program, Division of Infectious Diseases, Boston Children's Hospital, Boston, MA, USA

Dheeraj Soni

Precision Vaccines Program, Division of Infectious Diseases, Boston Children's Hospital, Boston, MA, USA <https://orcid.org/0000-0002-5555-2051>

Simone Schüller

Precision Vaccines Program, Division of Infectious Diseases, Boston Children's Hospital, Boston, MA, USA

Karthik Siram

Department of Biomedical and Pharmaceutical Sciences, University of Montana, Missoula, MT, USA

Etsuro Nanishi

Precision Vaccines Program, Division of Infectious Diseases, Boston Children's Hospital, Boston, MA, USA

Hélène G. Bazin

Department of Biomedical and Pharmaceutical Sciences, University of Montana, Missoula, MT, USA

David J. Burkhart

Department of Biomedical and Pharmaceutical Sciences, University of Montana, Missoula, MT, USA

Ofar Levy

Precision Vaccines Program, Division of Infectious Diseases, Boston Children's Hospital, Boston, MA, USA

Jay T. Evans (✉ jay.t.evans@inimmune.com)

Center for Translational Medicine, University of Montana, Missoula, MT, USA

Research Article

Keywords: TLR7/8, innate immunity, adjuvant development, Th1 polarization, Bordetella pertussis

Posted Date: June 1st, 2022

DOI: <https://doi.org/10.21203/rs.3.rs-1713108/v1>

License:  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published at Scientific Reports on October 18th, 2022. See the published version at <https://doi.org/10.1038/s41598-022-20346-w>.

Abstract

Infection is the most common cause of mortality early in life, yet the broad potential of immunization is not fully realized in this vulnerable population. Most vaccines are administered during infancy and childhood, but in some cases the full benefit of vaccination is not realized in-part. New adjuvants are cardinal to further optimize current immunization approaches for early life. However, only a few classes of adjuvants are presently incorporated in vaccines approved for human use. Recent advances in the discovery and delivery of Toll-like receptor (TLR) agonist adjuvants have provided a new toolbox for vaccinologists. Prominent among these candidate adjuvants are synthetic small molecule TLR7/8 agonists. The development of an effective infant *Bordetella pertussis* vaccine is urgently required because of the resurgence of pertussis in many countries, contemporaneous to the switch from whole cell to acellular vaccines. In this context, TLR7/8 adjuvant (TLR7/8A) based vaccine formulation strategies may be a promising tool to enhance and accelerate early life immunity by acellular *B. pertussis* vaccines. In the present study, we optimized a) the formulation delivery system, b) structure, and c) immunologic activity of novel small molecule imidazoquinoline TLR7/8As towards human infant leukocytes, including dendritic cells. Upon immunization of neonatal mice, this TLR7/8A overcame neonatal hyporesponsiveness to acellular pertussis vaccination by driving a T helper (Th)1/Th17 biased T cell- and IgG2c-skewed humoral response to a licensed acellular vaccine (DTaP). This potent immunization strategy may represent a new paradigm for effective immunization against pertussis and other pathogens in early life.

Introduction

Whooping cough is a respiratory infection caused by the Gram-negative encapsulated bacterium *Bordetella pertussis*, which can lead to severe complications and death, especially in newborns and young infants^{1,2}. Vaccination remains the most effective strategy to prevent whooping cough. According to the World Health Organization, worldwide vaccination programs started in the mid-20th century reduced the incidence of *B. pertussis* infection and associated mortality by 90%³. Currently employed aP vaccines significantly enhance protection against *B. pertussis* but require 5 doses starting from 2 months through 4–6 years of age and immunity can wane over time^{4,5}. As such, there remains a need for booster immunizations every 10 years in adults which results in low vaccination rates in this group, including pregnant women with inadequate anti-*B. pertussis* IgG^{6–8}, further contributing to suboptimal protection in neonates and infants. Notably, since 2010, up to 50,000 cases of whooping cough have been reported each year in the United States, interspersed with prominent epidemics⁹.

Given the global burden of pertussis infection, an improved infant *B. pertussis* vaccine is now urgently needed¹⁰. Although the majority of global immunization is pediatric, development of new *B. pertussis* vaccines has typically taken an *ad hoc* approach that disregards age-specific immunity in preclinical discovery and development, with an initial focus on adult vaccine trials¹¹. Limited vaccine immunogenicity and transient presence of neutralizing antibodies (Abs) are major challenges when

immunizing newborns and young infants¹². Historically, solutions to these challenges included increasing immunogenicity via use of multi-dose pediatric immunization schedules, expanding the length of time between vaccine doses and/or administration of doses later in infancy¹³, or increasing/modifying antigen-content¹⁴. While these approaches enhanced immunogenicity, they require multiple doses and waning immunity remains a challenge.

Novel adjuvant strategies tailored to enhance early life immunity represent an innovative approach to addressing limited vaccine immunogenicity in the very young¹⁵⁻¹⁸. Accordingly, the development of rationally designed vaccine formulations, which include adjuvants that more effectively enhance immune responses in childhood, is a promising approach¹⁹⁻²¹. In particular, there is an emerging interest in agonists of intracellular TLR7 and TLR8, endosomal pattern recognition receptors (PRRs) whose natural ligands are microbial RNA²². There may be benefit to dual activation of these pathways as TLR7 stimulation activates B cell proliferation, IgG production and class switching²³, while TLR8 is a vital PAMP (pathogen associated molecular patterns) receptor and facilitates T follicular helper cells (Tfh) cell differentiation by IL-12 signal cascade and is a promising target for Tfh cell-skewing vaccine adjuvants²². Of note, TLR7/8 agonists (TLR7/8As) are refractory to inhibitory plasma adenosine pathways in newborns^{21,24} and robustly activated the early life immune system *in vitro* and *in vivo*. Unlike agonists of most TLRs, that fail to elicit Th1 cytokine production from human newborn and infant leukocytes, TLR7/8-activating imidazoquinoline compounds (IMQs) induce robust Th1-polarizing responses in both human neonatal and adult dendritic cells (DCs)^{21,25,26}. TLR7/8 stimulation can also induce robust B cell responses in early life²⁷⁻²⁹. Addition of a TLR7A to acellular pertussis vaccine *in vivo* enhanced adult murine Th1 and Th17 responses and protective immunity³⁰, but corresponding data in infant animals to our knowledge are lacking.

Formulation science has traditionally been underappreciated in adjuvant discovery and development³¹. However over the past decade, with growing realization of the importance of formulation, the ability to develop more fully characterized vaccine formulations has become a major goal for many involved in the areas of vaccine development³². Formulation science has played a significant role in facilitating the delivery of TLR7/8As as vaccine adjuvants³³. Synthetic IMQ TLR7/8A small molecules formulated in an aqueous dispersion have limited adjuvant activity since they are prone to diffuse away from the injection site, which can also result in systemic cytokine induction and toxicity³⁴. Most notably, R848 has a poor tolerability profile when tested systemically in humans. Common systemic side effects of this aqueous formulation include injection site reactogenicity and flu-like symptoms (fever, headache and malaise) correlating to systemic immune activation, seen with high peripheral blood concentrations of numerous inflammatory cytokines^{35,36}. We have previously demonstrated that TLR7/8 adjuvantation can overcome newborn hyporesponsiveness to pneumococcal conjugate vaccination at birth³⁷. 3M-052, a locally-acting lipidated IMQ TLR7/8A adjuvant bearing a fatty acid tail (C18 lipid moiety), drove robust T helper 1-cytokine production by human newborn leukocytes *in vitro*, both alone and in synergy with the alum-adjuvanted pneumococcal conjugate vaccine (PCV)13³⁷. Moreover, a single administration of 3M-052 in

combination with PCV13 on the first day of life, accelerated and enhanced anti-*S. pneumoniae* polysaccharide-specific B cells, serotype-specific Ab titers, and Ab-mediated phagocytic killing, to serum concentrations ~ 10–100 times greater than a single birth dose of PCV13 alone. A very recent study also demonstrated the efficacy of 3M-052 in induction of HIV-1 envelope specific long-lived plasma cells and humoral immunity in non-human primates³⁸. These studies suggested that appropriately formulated TLR7/8A adjuvants, potentially co-administered with alum, can enhance responses to vaccines in newborns and young infants³⁷.

In this study, we demonstrate that immunization of newborn mice with TLR7/8A:Alum-adjuvanted DTaP vaccine drives an antigen specific Th1/Th17-polarized T cell response along with a balanced humoral response characterized by enhanced switch toward an IgG2a/c subclass. Rational design of precision adjuvants at the preclinical discovery and development phase may thus identify adjuvanted vaccine formulations that optimally shield vulnerable populations¹⁷. Such an approach may be broadly applicable, potentially closing the window of vulnerability to infections in early life.

Results

TLR7/8 agonist UM-3001 demonstrates robust induction of Th1- and Th2-polarizing cytokines in human newborn blood

The use of novel TLR7/8As as adjuvants has been pursued in recent years as an effective method to increase immune responsiveness to several different vaccines and antigens^{33,39}. To determine if these compounds are also able to adjuvant the immune response to the aP vaccine, six novel imidazoquinoline (IMQ) and oxoadenine (OA) scaffold-based compounds were synthesized as described previously^{40–42} and evaluated. Three IMQ compounds, UM-3001, UM-3008 and UM-3009 (Fig. 1A, B) and three OA compounds, UM-3002, UM-3010 and UM-3011 (Fig. 1A, B), had variable TLR7 and TLR8 selectivity and potency in HEK293 assay (Fig. 1C, D). The precise structure-activity-relationship leading to the TLR7 and TLR8 selectivity and potency of these TLR7/8As has been reported previously^{39,41,42}, UM-3001 had the greatest potency for both hTLR7 and hTLR8 (Fig. 1C-E).

We next tested the ability of the core IMQs and OAs to induce concentration-dependent cytokine production in *in vitro* human neonatal and adult whole blood assays (Fig. 2A-D). While the vehicle control did not induce TNF or IFN γ production, all six of the TLR7/8As tested demonstrated titration-dependent induction of TNF (Fig. 2A) and IFN γ (Fig. 2B) from newborn blood. Interestingly, UM-3001 demonstrated adult-like potency and effectiveness with respect to induction of TNF production in newborn cord blood (Fig. 2C). Of note, UM-3001 demonstrated the greatest potency, effectiveness and IFN γ polarization in newborn cord blood. UM-3001-induced IFN γ production in newborn blood was most evident at 10 μ M, reaching ~ 900 pg/ml, twice the IFN γ concentration produced in similarly stimulated adult blood (Fig. 2D, $p < 0.05$).

UM-3001 also demonstrated a broader ability to induce a newborn-specific cytokine and chemokine potency and polarization. Supernatants derived from stimulated whole blood assays were analyzed for cytokine/chemokine/interferon expression by multiplex assay. Results were graphed as fold change for newborn blood (blue line) over adult (black line), at both a low (1 μ M, Fig. 2E, Table S1) and high (10 μ M, Fig. 2F, Table S1) concentration of UM-3001 which demonstrated concentration-dependent robust accumulation of all cytokines tested including IL-1 β , IL-6 and IL-10 (Fig. 2E, F, Table S1). UM-3001 also induced significant production of chemokines including CXCL8 and CCL2 as well as GM-CSF in stimulated human newborn- vs adult blood (Fig. 2E, F, Table S1).

Next, we employed a human newborn Th1 polarization assay, which leveraged the intrinsic characteristics of the newborn T cell compartment, composed mainly of naïve T cells, to evaluate how UM-3001-induced T cell polarization in a mixed mononuclear cell culture in the presence of a T cell receptor (TCR)-mediated stimulus (Fig. S1A). Additionally, cord blood mononuclear cells (CBMCs) were cultured in the presence of autologous plasma, a rich source of age-specific soluble immunomodulatory factors to closer mimic *in vivo* conditions⁴³. Neonatal CBMCs stimulated for 96 h (hrs) with α CD3 (polyclonal T cell activator) and 10 μ M of UM-3001 demonstrated significantly enhanced production of IFN γ by newborn T cells (Fig. S1B, $p < 0.05$).

Targeted lipidation changes the immunostimulatory properties of the IMQ scaffold

Upon determining that these agonists, and UM-3001 in particular, significantly enhance newborn TNF and IFN γ responses, we further explored their utility as adjuvants upon derivatization using lipid conjugation. Locally acting adjuvants may have distinct advantages *in vivo* by avoiding extensive systemic distribution and consequent induction of systemic inflammation⁴⁴⁻⁴⁶. In addition, cellular uptake is a prerequisite for cellular activation in response to TLR7/8As since these receptors are localized in the endosomal/lysosomal compartments⁴⁷. Accordingly, there is interest in strategies to increase the penetration of the TLR7/8As into the endosome of DCs and other immune cells which, in addition to targeting potent response, may also ameliorate potentially reactogenic or low-level toxic side-effects. In this context, lipid conjugation of nucleoside drugs including TLR7/8As⁴⁸ can facilitate endocytosis, enhance oral bioavailability, and decrease systemic side effects by creating a depot effect. The basic IMQ pharmacophore was optimized to contain a 2 *n*-butyl and 1 ethanol groups creating UM-3001 (Fig. 3). For nucleolipidation studies this core was further derivatized by phospholipidation⁴⁹ off the ethanol at the 1 position, followed by addition of an optimally determined 3 polyethylene glycol (PEG) linker⁵⁰ (Fig. 3A). Of note, UM-3001 core compound does not contain a phosphate moiety and thus cannot adsorb to alum (Table S2), a common vaccine component serving as an adjuvant and antigen stabilizer and addition of a phosphate or phospholipid on the core can facilitate alum adsorption. Addition of the PEG linker between the phosphate and lipid moiety, to UM-3001 substantially changed the agonist's cytokine skewing properties from pro-inflammatory biased, TNF production, to type I interferon-biased (data not shown). Of note, while potency and efficacy with respect to TNF induction was directly correlated with the number of PEG units, for IFN α , the structure activity relationship (SAR) was less clear, although the >3 PEG linker compound displayed greater efficacy and potency for induction of this cytokine (data not

shown). This change in phenotype informed selection of a compound with 3 PEG units (hereby UM-3003), that displayed a skewed type I interferon response with minimal inflammatory cytokine production suggesting it would have reduced reactogenicity while maintaining immunogenicity.

Lipidated TLR7/8 agonist rapidly and fully adsorbed onto alum

Collectively, these observations support the potential of both the core and lipidated molecules to serve as immunomodulatory vaccine adjuvants. To investigate the ability of these novel TLR7/8As to augment response to aP vaccine, we characterized their ability to enhance immunogenicity of a commercially utilized, Food and Drug Administration (FDA) approved, pediatric DTaP vaccine (Trade name: *Infanrix*). The acellular vaccine contains three recombinant *B. pertussis* proteins, the inactivated pertussis toxin (PT), the adhesin filamentous hemagglutinin (*FHA*), and outer membrane protein, pertactin (PRN). All three proteins are unstable unless adsorbed to aluminum hydroxide (alum). The nucleolipid derivative compound(s) contain phosphate groups which should theoretically adsorb to alum in the aP vaccine. Accordingly, we undertook an adsorption study to determine how the different IMQ adjuvant compounds would interact with the final vaccine antigen formulation (DTaP). Aqueous suspensions of the lipidated compound UM-3003 and its parent pharmacophore UM-3001 were incubated with DTaP vaccine and aliquots were assayed at various time points (1, 2, 24 h) post admixture to assess amounts of unbound compounds in the supernatant via reversed-phase high-performance liquid chromatography (RP-HPLC). As suspected, the lipidated compound fully adsorbed (~96 – 100 %) to the alum/antigen within 1 h (Table 1). The addition of excess alum, through pre-adsorption of the compound on the alum, had little effect on UM-3003 adsorption (~99 % after 1 h) (Table 1, top panel). However, under all conditions tested, the core UM-3001 compound demonstrated very limited ability to adsorb to aP vaccine- i.e., ~ 4 - 7 % within 1-2 h (Table S2), with peak area intensity levels similar to the unmixed controls. This was further addressed by investigating adsorption strength and the desorption profile of UM-3003 from alum.

Predicable *in vitro* release and desorption kinetics of lipidated TLR7/8 agonist from alum

The presence of various ions in plasma including calcium, potassium, sodium, magnesium, phosphate, chloride, bicarbonate, etc., can facilitate desorption of the adsorbed compounds from the surface of alhydrogel by ligand exchange⁵¹. To evaluate the adsorption strength and desorption profile of UM-3003 from its adsorbed form on alhydrogel, we performed *in vitro* release and desorption studies upon exposure to plasma over a period of 24 h. The *in vitro* release and desorption profiles of UM-3003 from UM-3003 adsorbed alhydrogel formulations are shown in Fig. 3B. Without agitation and periodical replenishment of the release medium, ~18% of UM-3003 was desorbed from a UM-3003-adsorbed alhydrogel formulation, suggesting strong adsorption of UM-3003 onto alhydrogel. The amount of UM-3003 desorbed from alhydrogel increased to ~90% with agitation and periodical replenishment of the release medium with fresh adjuvant-free human plasma, suggesting enhanced desorption. Periodical replenishment with fresh adjuvant-free human plasma likely provided additional ions to desorb UM-3003 from the surface of alhydrogel by ligand exchange. To identify the most likely mechanism of release of UM-3003 from UM-3003 adsorbed alhydrogel formulation, the release profile was fitted with various

kinetic models such as zero order ($R^2 = 0.73$), first order ($R^2 = 0.51$), Higuchi, Korsmeyer-Peppas ($R^2 = 0.7540$; $n = 0.283$) and Hixson-Crowell (0.36). The results indicated that Korsmeyer-Peppas model was suitable to explain the mechanism of release of UM-3003 from alhydrogel. A corresponding n value of 0.283 in this model indicated that UM-3003 desorbed from alhydrogel *via* Fickian diffusion i.e., the release of UM-3003 in the release medium was from a region of higher concentration to lower concentration⁵². Lastly, UM-3003 in 2% glycerol presented with an average particle size of ~ 150 nm, a pH of ~ 9.4 and a polydispersity index of 0.33 (Fig. 3C). This aqueous formulation of UM-3003 is suitable for sterile filtration due to its low particle size and facilitates facile adsorption to alhydrogel by direct addition.

Lipid adsorption to Alum unlocks TLR7/8 adjuvanticity

Formulations of DTaP:TLR7/8A were next tested for immunogenicity and dosing in adult BALB/c and C57BL/6 mice. First, BALB/c mice were immunized twice, 14 days apart with *Infanrix* (1/100th of the human dose) \pm UM-3001 or UM-3003 at 0.1, 1 or 10 μg per mouse in different formulations. Serum was harvested 14 days following prime and boost (Fig. S2A). At two weeks post primary vaccination, anti-FHA IgG2a serum Ab titers were significantly elevated (~ 16 fold) over *Infanrix* alone vaccinated mice when 10 μg of UM-3003, with ($p < 0.002$) or without alum ($p < 0.002$) pre-adsorption of the adjuvant, was included in the vaccine (Fig. S2C). IgG1 anti-FHA titers were only significantly boosted (~ 4 fold) with UM-3003 pre-adsorbed on alum ($p < 0.001$) (Fig. S2B) compared to *Infanrix* alone vaccinated mice demonstrating a potential difference in effect for alum adsorption in driving a balanced Th1/Th2 immune response or a preferred Th1 response. By 14 days post-secondary immunization serum anti-FHA titers were much higher than *Infanrix* alone and nearing a plateau for many groups (Fig. S2D, E). Again, we noted that addition of UM-3003 both with and without pre-alum adsorption facilitated significantly higher IgG1 and IgG2a Ab titers. For both 14 days post-primary and -secondary immunization of adult mice, addition of the core IMQ UM-3001 did not enhance either IgG1 or IgG2a Ab titers. Of note, increase of IgG2a Ab titers during secondary immunization were observed when boosting with a 10 μg dose UM-3003 alone ($p < 0.001$) and a 0.1 μg dose UM-3003 pre-adsorbed on alum (Fig. S2E, $p < 0.002$).

Next, DTaP:TLR7/8A induced immunogenicity in adult C57BL/6 mice was confirmed (Fig. 4), with the IgG2c induced phenotype mirroring those observed in BALB/c mice. At two weeks post-secondary vaccination of DTaP (1/100th of human dose) with 10 μg of UM-3003, anti-FHA and anti-PRN IgG2c serum Ab titers were significantly elevated over DTaP alone ($p < 0.001$ and $p < 0.033$, respectively) or with additional alum (10 μg , $p < 0.001$ and $p < 0.002$, respectively) (Fig. 4D, H). A higher IgG2c/IgG1 ratio (around or over 1) was observed in UM-3003 adjuvanted groups suggesting Th1 biased Ab response (Fig. 4E, I). Via evaluation of FHA- and PRN-specific memory T cell responses post vaccination, we also confirmed intracellular IFN γ production by splenic effector CD44⁺ CD4⁺ T cells (which denotes Th1 skewed response) from DTaP:TLR7/8A immunized mice (Fig. 4J, K) following antigen (both FHA and PRN) stimulation. Additional alum adjuvantation alone did not play any significant role to stimulate DTaP experienced T cells (data now shown). A similar trend was observed when IFN γ secretion by splenocytes, measured by multiplex assay from adult immunized mice following stimulation for 72-80 h (Fig. S4A, D),

where both DTaP:TLR7/8A formulations enhanced antigen specific Th1-cytokine shifts compared to DTaP alone.

TLR7/8 stimulation of neonatal MoDCs elicits a mixed Th polarizing innate cytokine response

As antigen presenting cells are the key target for candidate adjuvants, we compared concentration-dependent responses (0.1 mM to 10 mM) of UM-3001 and UM-3003 *in vitro* with human adult and neonatal MoDCs (Fig. 5A-D, Table S3A, B, Fig. S5). Cytokine-inducing activity of UM-3003 was also tested in newborn mononuclear cell culture in the presence of α -CD3 which triggers TCR stimulation (Fig. 5E, F, Table S3C, D). This approach was employed to assess the impact of formulation and/or lipidation to modulate the ability of a TLR7/8A to activate MoDCs and/or polarize T cells. Both the TLR4A LPS and UM-3003 induced TNF, which polarizes Th1 cells (Fig. 5A-C). UM-3003, tested at up to 10 mM, significantly induced TNF in newborn MoDCs as compared to vehicle control (Fig. 5C). TLR8 is a vital PAMP receptor that mediates IL-12 production and T_{FH} differentiation²². Consistent with our prior studies of other TLR7/8As^{26,28}, UM-3003 induced IL-12p70 production in human adult (Fig. S5) and newborn MoDCs (Fig. 5A, B, D and Table S3B). Overall UM-3003 was an effective activator of human MoDCs *in vitro*.

To further characterize Th-polarizing cytokine induction, the ability of UM-3003 to induce Th1/Th2/Th17 response was tested after TCR stimulation in human neonatal PBMCs (Fig. 5E, F, Table S3C, D). The stimulator of interferon genes (STING) ligand 2'3'-cGAMP coordinates Th1-biased humoral and cell mediated immunity⁵³. 2'3'-cGAMP along with the TLR7/8A CL075 served as positive controls for TCR stimulation⁵⁴. UM-3003 induced robust IL-17 production after α -CD3 stimulation (Fig. 5E, F, Table S3D). In contrast, the control Th1 agonist 2'3'-cGAMP + CL075 induced a Th1 polarized response (Table S3D) with no increase in Th17. Induction of these Th1- and Th17-polarizing cytokines upon TCR stimulation highlights the potential of UM-3003 as a candidate adjuvant to enhance immunogenicity of an acellular pertussis vaccine.

Combined adjuvantation with TLR7/8A:alum drives neonatal Th1-polarized responsiveness to DTaP

Having demonstrated the potential of Alum:UM-3003 to enhance both immunogenicity of *Infanrix* and Ab subclasses induction in adult mice, we next assessed its activity in newborn mice. Of note, vaccines adjuvanted solely with alum typically drive Th2 responses at the expense of Th1 immunity and fail to induce Ab isotype switching toward IgG2c in early life⁵³. 7 days old C57BL/6 were vaccinated with a prime-boost schedule (Fig. 6A) comprised of a two-injection series administered at Day of Life (DOL) 7 and 14 with DTaP (*Infanrix*) (1/100th of the human dose) \pm UM-3001 (which did not induce adjuvanticity, Fig. S6) or UM-3003 at 10 μ g per mouse. Serum was harvested 14 days following boost (at DOL 28) to measure Ab production. At two weeks post-secondary vaccination of DTaP (1/100th of human dose) with 10 μ g of UM-3003, anti-FHA and anti-PRN IgG2c serum Ab titers were significantly elevated over DTaP alone ($p < 0.002$ and $p < 0.001$, respectively) or with additional alum (10 μ g, $p < 0.001$) (Fig. 6D, H), with a Th1 biased IgG2c/IgG1 ratio (Fig. 6E, I). Evaluation of infant FHA- and PRN-specific memory CD4⁺ T cell

responses confirmed intracellular IFN γ production and thus Th1 polarization among DTaP:TLR7/8A immunized mice (Fig. 6J, K). In addition, we observed formulated DTaP with UM-3003 induced FHA-specific polyfunctionality (Th2/Th17) responses in infant mice (Fig. 6J). As compared to DTaP alone, a highly consistent DTaP:TLR7/8A FHA-specific IFN γ secretion by neonatal splenocytes was also observed (Fig. S4G, $p < 0.002$). Remarkably, we demonstrate that, compared to DTaP alone, TLR7/8 adjuvantation increased FHA-specific IFN γ responses ~6-8-fold increase in infant mice, as compared to ~2-2.5-fold increase for their adult counterparts (Fig. 6L). These observations highlight the age-specific nature of the DTaP:TLR7/8A formulation and suggest that our *in vitro* Th1-polarizing leukocyte studies predict *in vivo* activity.

Discussion

B. pertussis is an important cause of childhood morbidity and mortality, yet current vaccination strategies for newborns and infants are suboptimal. There is an unmet need to develop a more effective infant pertussis vaccine because of the resurgence of pertussis in many countries and the continued phenomena of waning immunity in older infants and adults⁵⁵. Current alum-adjuvanted acellular pertussis (aP) vaccines have shortcomings which may contribute to suboptimal infant responses⁵⁶. New precision adjuvants, selected based on their activity towards a target age group, may enable development of next generation vaccines to optimize protection of vulnerable populations. Such an approach could in principle enhance early life immunogenicity by creating a vaccine formulation that induces both accelerated and robust immunity to *B. pertussis*. In the present study, we explored the adjuvant potential of imidazoquinoline (IMQ) small molecule TLR7/8 agonists by assessing their robust activity in inducing Th-polarizing cytokines from human newborn leukocytes *in vitro*, generating a phospholipidated derivative (UM-3003) and adsorbing it onto alum thereby generating a combined adjuvantation system (UM-3003:Alum). In a neonatal mouse immunization model, addition of (UM-3003:Alum) induced a balanced Th1/Th17-polarized cell mediated and IgG2c-skewed humoral response to a licensed acellular vaccine (*Infanrix*). TLR7/8As:Alum represents a promising adjuvant combination that may enable an improved pertussis vaccine to optimally protect the very young.

The persistently high global burden of infections in the very young⁵⁷ provides a compelling rationale for developing additional safe and effective early life vaccines. Small molecule TLR7/8As have demonstrated great potential as vaccine adjuvants^{38,58}, since they directly activate APCs and can enhance both humoral and cellular immune responses, especially Th1 responses⁵⁹. Along with effective adjuvantation, vaccine delivery systems, improvement in antigen design and increased knowledge about human immune responses, are key technological advances fueling the current revolution in vaccine discovery and development⁶⁰. Rational vaccine design approaches, employing immuno-engineering and novel delivery systems may enable controlled preparation of vaccine complexes of the desired immunostimulatory properties, particulate size, and antigen load, all of which also improve safety by potentially limiting systemic toxicities by their targeted nature^{17,61}.

Overall, there are several synthetically designed TLR7/8 adjuvanted vaccine formulations at various stages of clinical development, which may offer significant advantages compared to current alum-based subunit vaccines consisting of complex and heterogeneous products. Benzonaphthyridine (BZN) TLR7 agonists have been chemically modified with phosphonates to enable adsorption onto alum hydroxide^{58,62}. The adsorption of TLR7/8 adjuvants to alum shares some similar advantages to lipidation and encapsulation, such as i) exploiting the inherent adjuvanticity of alum, ii) facilitating simultaneous co-delivery antigen and adjuvant, while also iii) retaining the small molecule adjuvant at the site of vaccination, thereby limiting the systemic distribution of the adjuvant⁵⁸. TLR7/8 agonists have demonstrated significantly enhanced adjuvanticity in the context of several licensed vaccine classes, including formulation with: recombinant group B meningococcus (MenB) proteins alone or with the full 4-component alum-adjuvanted MenB vaccine formulation (4CMenB, Trade name: *Bexsero*)⁵⁸, the glycoconjugate CRM197-MenC vaccine (Trade name: *Menjugate*)⁶³ and a tetanus, diphtheria, and acellular pertussis (whooping cough) (DTaP) vaccine³⁰. Of note, TLR7/8 adjuvantation approaches have opened up an opportunity to shape responses to diseases that are often characterized as non-vaccine preventable⁶¹, including *Staphylococcus aureus* and HIV. A recent report by our group suggested that novel lipidated TLR7/8 agonists are effective adjuvants that can trigger influenza-virus specific Th1/Th17 polarization and humoral responses in mice⁵⁹. In a phase I randomized, dose escalation clinical study of an AS37-adjuvanted meningococcal C conjugated vaccine (i.e., Alum + TLR7A) appears safe and well tolerated in adults⁶⁴. This also extends to viral infections, where TLR7/8As can significantly improve vaccine efficacy, leading to improved survival post challenge, such as for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and influenza virus (H1N1) vaccines⁶⁵. Continued evaluation and optimization of these TLR7 and TLR7/8 adjuvant approaches, including potential dose-sparing effects, decreased reactogenicity, increased safety, and efficacy profiles, are clearly merited³³.

Our study synergistically combined three innovative approaches to provide unique insight into and overcome early life aP vaccine hypo-responsiveness: 1) use of age-specific human *in vitro* and murine *in vivo* models, 2) employing cutting-edge medicinal chemistry and 3) leveraging formulation science to optimize small molecule adjuvanticity and delivery. Next generation pertussis vaccines will likely require optimization of antigens and adjuvantation to enhance immunogenicity while maintaining relatively low reactogenicity.

The ability of UM-3003 to induce TNF and IL12p70 production by neonatal MoDCs as well as Th17-polarization by neonatal T cells (albeit FHA-specific) is notable. Activated MoDCs initiate distinct signaling cascades and polarize CD4⁺ T helper cells. Acellular pertussis vaccine mostly induced Th2 polarization which may contribute to waning immunity^{66,67}. As compared to other pharmacophores with TLR7/8 agonism, UM-3003 induces a more balanced Th-polarizing innate cytokine environment upon TCR stimulation. Our results raise the possibility that an appropriately formulated DTaP adjuvanted with UM-3003, which induces a Th1/17-response similar to that achieved by whole cell vaccination or natural pertussis infection, may induce immunity to prevent transmission of pertussis infection and long-term

lasting protective immunity. One unavoidable shortcoming worth highlighting of studies such as ours, that focus on TLR7/8 agonist adjuvant development, is the reduced applicability of pertussis challenge model in mice. IMQs trigger TLR7/8 pathway in a species-specific manner, with murine TLR8 being most distinct, and not activated by the majority of known human specific TLR8 agonists³³. Interestingly, pig and non-human primate TLR8 innate immune responses are very similar to those observed in humans³³. Therefore, it remains to be assessed whether Abs induced by UM-3003-adjuvanted DTaP can prevent infection with *B. pertussis in vivo*, a topic worthy of future study by using pigs and non-human primates.

In summary, we demonstrate that (a) UM-3003 robustly activates human neonatal MoDCs *in vitro* to produce IL-12p70 and (b) upon immunization of newborn mice *in vivo*, UM-3003:Alum-adjuvanted DTaP vaccination enhanced FHA- and PRN-specific Th1/Th17 cell mediated immunogenicity, including switched humoral responses toward the highly functional IgG2a/c subclass, which better mimics cellular immunity profiles triggered by natural *B. pertussis* infection and DTwP vaccination⁶⁸. By combining age-specific early life human *in vitro* and mouse *in vivo* models, medicinal chemistry and formulation science, as well as benchmarking to licensed vaccines, our study provides a fresh paradigm for precision vaccine design to inform development of novel age-targeted development of neonatal and pediatric vaccines. This precision adjuvantation approach may be of fundamental importance in vaccine discovery and development and could represent a new paradigm for effective early life immunization against pertussis and other pathogens.

Methods

Ethics statements. All experiments were conducted in accordance with relevant institutional and national guidelines, regulations, and approvals. All experiments involving animals were approved by the Institutional Animal Care and Use Committees (IACUC) of Boston Children's Hospital and Harvard Medical School (protocol numbers 19-02-3792R and 19-02-3897R) and the University of Montana (protocol number 037-16ASDBS-061416). C57BL/6 and BALB/c mice were obtained from Taconic Biosciences (Rensselaer, NY), Jackson Laboratories (Bar Harbor, ME) or Envigo (Indianapolis, IN) and housed in specific pathogen-free conditions in the animal research facilities at Boston Children's Hospital or the University of Montana. For breeding purposes, mice were housed in couples, and cages checked daily to assess pregnancy status of dams and/or the presence of pups. Discovery of a new litter was recorded as DOL 0. Both male and female pups were used for neonatal experiments in a littermate-controlled specific manner. Non-identifiable human cord blood samples were collected with approval from the Ethics Committee of The Brigham & Women's Hospital, Boston, MA (protocol number 2000-P-000117) and Beth Israel Deaconess Medical Center Boston, MA (protocol number 2011P-000118). Blood samples from adult volunteers were collected after written informed consent with approval from the Ethics Committee of Boston Children's Hospital, Boston, MA (protocol number X07-05-0223) or the University of Montana Institutional Review Board (protocol number 43 - 16).

Human blood sample processing and *in vitro* stimulation. Peripheral blood was collected from healthy adult volunteers, while human newborn cord blood was collected immediately after Cesarean section

delivery of the placenta. Births to known HIV-positive mothers were excluded. Human experimentation guidelines of the U.S. Department of Health and Human Services, The Brigham & Women's Hospital, Beth Israel Deaconess Medical Center Boston, Boston Children's Hospital and the University of Montana were observed, following protocols approved by the local institutional review boards.

Human blood was anti-coagulated with 20 units/ml pyrogen-free sodium heparin (American Pharmaceutical Partners, Inc.; Schaumburg, IL). All blood products were kept at room temperature and processed within 4 h from collection. Human whole blood assays were completed as previously described^{25,28}. Briefly, neonatal cord blood or adult whole blood (WB) was mixed 1:1 with sterile pre-warmed (37° C) RPMI 1640 medium (Invitrogen; Carlsbad, CA) and 180–225 µl of the 1:1 suspension was added to each well of a 96 well U-bottom plate (Becton Dickinson; Franklin Lakes, NJ, USA) containing 20–25 µl freshly prepared specific TLRAs at 10x the final concentration. Suspensions containing 200–250 µl/well were gently mixed by pipetting and incubated for 6 h at 37°C in a humidified incubator at 5% CO₂. After culture, plates were centrifuged at 500 x g and ~ 100–150 µl of supernatant was carefully removed by pipetting without disturbing the cell pellet. Supernatants derived from human leukocyte stimulations were assayed by ELISA for TNF and IFN γ (BD Biosciences; San Jose, CA, USA).

For adult PBMC and neonatal CBMC stimulation, primary human PBMCs and CBMCs were isolated from fresh blood via Ficoll gradient separation. PBMCs and CBMCs were resuspended and maintained in RPMI-1640 culture media (Invitrogen, Grand Island, NY), antibiotics (Pen/Step/Glut, Invitrogen) and 10% FBS (Sigma). Cells were plated at 0.1 x 10⁶ cells/well in 96-well tissue culture plates and stimulated for 24 h with aqueous formulations of indicated compounds. Culture supernatants were harvested and analyzed for IFN α and TNF induction using human TNF DuoSet (R) ELISA kit and human IFN α VeriKine ELISA kit (Pestka Biomedical Laboratories, Inc., Piscataway, NJ).

Additionally, for both newborn and adult *in vitro* assays, cytokine and chemokine expression profiles in cell culture supernatants and peripheral blood plasma were measured using customized Milliplex human cytokine/chemokine magnetic bead panels (Millipore; Billerica, MA, USA). Assays were analyzed on the Luminex® 100/200™ System employing xPOTENT® software (Luminex; Austin, TX) and Millipore Milliplex Analyst (version 3.5.5.0). The minimum threshold for each analyte was set at the minimum detectable concentration for a given assay, defined as three standard deviations above the mean background. CL075 (TLR8/7) and R848 (TLR7/8) were purchased from InvivoGen (San Diego, CA) and used at the concentrations noted in the figure legends.

Endotoxin evaluation and HEK293 assay for human TLR7 and TLR8 selectivity.

All TLR7/8As used in both *in vitro* and *in vivo* studies were verified to be free of endotoxin (< 1 EU/ml) by the Endosafe nexgen-MCS *Limulus amoebocyte lysate* assay per the manufacturer's instructions (Charles River Laboratories). Human embryonic kidney (HEK)293 cells expressing human TLR7 or TLR8 with an NF- κ B-responsive secreted embryonic alkaline phosphatase (SEAP) reporter gene were obtained from Novus Biologicals (Littleton, CO) and Invivogen (San Diego, CA), respectively. Cells were maintained in

DMEM with 10% HI-FBS and selection antibiotics per the manufacturer's instructions. Cells were plated at 5×10^5 cells/96-well and stimulated with indicated agonist(s) for 24h. Supernatants were harvested and analyzed for NF- κ B/SEAP activation using the QuantiBlue kit (Invivogen). Values are expressed as fold change in OD₆₅₀ over vehicle-only treated samples.

Human newborn Th1/Th17 polarization assay. Human newborn cord blood mononuclear cells (CBMCs), a mixed mononuclear cell culture of which the T cell compartment is largely composed of naïve T cells, were stimulated with the TLR7/8A or STING agonist (2'3'-cGAMP) in the presence of the polyclonal T cell activator α CD3 (Plate-bound, 5 μ g/ml) for 96 h. T cell polarization was evaluated by a high sensitivity T cell multiplex assay.

Quantification of UM-3003 adsorption onto alum derived from DTaP vaccine. To quantify the extent of UM-3003 adsorption to aluminum hydroxide (Alhydrogel) we mixed 100 μ l of UM-3003 with 100 μ l of *Infanrix* (GSK) (combination vaccine for diphtheria, tetanus, and acellular pertussis (DTaP)) (a 1:10 UM-3003:alum mass ratio) plus 300 μ l of 0.9% saline. After vortexing for 10 seconds the sample was placed in a 37°C incubator. Every 15 minutes the sample was vortexed for an additional 5 seconds and placed back into the incubator. Aliquots (0.75 ml) were taken at t = 0.25, 0.5, 1, 2, 4 and 24 h and centrifuged at 3000 RPM (rcf = 664 g) to separate the alum from the supernatant. Supernatant was immediately removed and placed into an autosampler vial undiluted for analysis by reverse-phase high performance liquid chromatography (RP-HPLC) to determine adsorption as a function of time. RP-HPLC samples were run on a Waters 2695 HPLC equipped with a 2996 photodiode array detector at a wavelength of 254 nm. A gradient was performed using a two mobile phase system of 0.1% trifluoroacetic acid in water and 0.1% trifluoroacetic acid in acetonitrile, on an Agilent Zorbax Eclipse Plus C18, 4.6 x 150 mm, 5 micron column at 25°C. The response (peak area) of the samples were compared against a 50 μ l UM-3003 plus 200 μ l 0.9% saline control and a separate 100 μ l alum plus 400 μ l saline control.

In vitro release and desorption kinetics of UM-3003. *In vitro* release and desorption kinetics of UM-3003 from UM-3003 adsorbed alhydrogel formulation were performed using 100% adjuvant-free human plasma as the release medium to simulate *in vivo* conditions. For the *in vitro* release experiment, 50 μ l of UM-3003 adsorbed alhydrogel formulation was mixed with 500 μ l of adjuvant-free human plasma in a closed glass vial at 37°C and gently stirred at 100 rpm. At different time points (0.25, 0.5, 1, 2, 4, 6, 10, and 24 h), 55 μ L of the release medium was collected and replenished with a fresh 55 μ l of adjuvant-free human plasma to simulate the *in vivo* sink conditions^{69,70}. *In vitro* desorption experiments were carried out similarly to the *in vitro* release study protocol without stirring the release medium and without replenishing the release medium. Following *in vitro* release and desorption studies, the plasma samples were centrifuged at 8,500 rpm for 5 minutes to pellet the UM-3003 adsorbed alhydrogel formulation. The supernatant (50 μ l), which contained desorbed UM-3003 was collected and retained at 2–8°C until further analysis by RP-HPLC. The amount of UM-3003 present in the samples was quantified by RP-HPLC after extraction. To identify the mechanism of release of UM-3003 from the alhydrogel adsorbed formulation, the *in vitro* release profile was fitted with various kinetic models such as zero order, first order, Higuchi,

Korsmeyer-Peppas and Hixson-Crowell using DD solver, using a Microsoft Excel plugin⁷¹ followed by Heat-Map transformation.

In vivo rodent immunization, antigens and Ab quantification. For immunization experiments, both neonate and adult mice were immunized intramuscularly (i.m.) in the posterior thigh with 50 µl of total vaccine dose. For adult mouse studies, either BALB/c mice or C57BL/6 (6–8 weeks of age) were immunized with Infanrix (1/100th of the human dose) ± UM-3001 or UM-3003 at 0.1 µg, 1 µg or 10 µg per mouse in different formulations (aqueous choline salt or alum pre-adsorbed) or alum at 10 µg per mouse. Serum was harvested 14 days following prime (14dp1) or boost (14dp2) and anti-FHA or anti-PRN serum Ab IgG, IgG1 and IgG2a/IgG2c titers were measured by ELISA, as described below. For neonatal mouse studies, 7 day old C57BL/6 mice were immunized with a prime-boost schedule (two injections, each one week apart, for newborn mice at DOL 7 and 14). Serum was harvested 14 days following boost (14dp2) (day of life 28) and anti-FHA or anti-PRN serum total IgG titers, IgG1 and IgG2c were measured by ELISA.

For anti-filamentous hemagglutinin (FHA) or anti-pertactin (PRN) ELISAs, CoStar 96 well high-binding plates (Corning, Corning, NY) were coated with either 2 µg/ml FHA (BP-FHA-100, The Native Antigen Company/Cedarlane, Burlington, NC) or 1 µg/ml PRN (*B. pertussis* Pertactin, Strain: *B. pertussis* strain 165, The List Labs, St Campbell, CA) in carbonate buffer pH 9.6, incubated overnight at 4°C, washed 3x with wash buffer (KPL 10X Phosphate Buffered Saline with 0.05% Tween 20 (Fisher Scientific)) and blocked with Superblock (ScyTek) for 1 h at room temperature (RT). Then, sera from vaccinated mice were added with an initial dilution of 1:100 and 1:2 serial dilutions in EIA buffer (PBS + BSA 1% + Tween 20 0.1% + Heat inactivated FBS 10%) and incubated for 2h at RT. Plates were then washed 3x and incubated for 1h at RT with HRP-conjugated anti-mouse IgG, IgG1, IgG2c or IgG2a (Southern Biotech). At the end of the incubation plates were washed 5x and developed with BD OptEIA TMB substrate reagent set (BD, San Jose, CA) for 10 minutes, then stopped with 1 M H₂SO₄. The optical density was measured at 450 nm with SpectraMax ID3 microplate reader with SoftMax Pro Version 5 (both from Molecular Devices) and either titers or concentrations were calculated using as cutoff three times the optical density of the background.

Cell mediated immune responses in rodents. After two weeks post booster-immunization, mice spleens were collected in RPMI 1640 media containing 10% heat-inactivated FBS. For analysis of single-cell suspensions, spleens were mechanically and aseptically dissociated with the back of a syringe plunger and filtered through a 70-µm cell strainer and collected in RPMI 1640 media. After centrifugation (500 x g, 10 mins, RT), cells were treated with 1 ml ACK lysis buffer (Gibco, Waltham, MA) for 2 min at RT to lyse red blood cells. Cells were washed immediately with RPMI 1640, passed through 70-µm cell strainer, and suspended in RPMI 1640 media (supplemented with 10% heat-inactivated FBS). Splenocytes were plated at a density of up to 2 × 10⁶ cells/well in a 96-well U-bottom plate and stimulated with 2 µg/ml of either FHA or PRN in T cell media. T cell media consists of RPMI 1640 (Gibco, Waltham, MA) supplemented with 10% heat-inactivated FBS (Cytiva HyClone, Fischer Scientific), 100 U/ml Penicillin and 100 mg/ml Streptomycin (Gibco, Waltham, MA), 55 mM 2-mercaptoethanol (Gibco, Waltham, MA), 60 mM Non-essential Amino Acids (Gibco, Waltham, MA), 11 mM HEPES (Gibco, Waltham, MA), and 800 mM L-

Glutamine (Gibco, Waltham, MA). In addition to antigen, the stimulation cocktail consisted of 1 µg/ml anti-mouse CD28/49d (BD Biosciences) as a co-stimulant.

For intracellular cytokine staining (ICS), 18 h stimulation was completed in a humidified incubator at 37°C, 5% CO₂, with 5 µg/ml Brefeldin A (BFA; BioLegend) was added during the last 6 h of stimulation, to block the cytokines production and facilitate optimal intracellular flow cytometry analysis. For quantification of antigen specific IFN γ and IL-17 responses by murine T cell multiplex assay, stimulation was done for 72–80 h of time period without any addition of BFA. Supernatants were collected and stored at -80°C for further analysis.

Intracellular cytokine staining and flow cytometry. After 18h of stimulation, cells were washed twice with PBS and blocked with Mouse Fc Block (BD Biosciences) according to the manufacturer's instructions. After blocking, cells were washed once with PBS and stained with Aqua Live/Dead stain (Life Technologies, Carlsbad, CA) for 15 min at RT. Following two additional PBS washes, cells were resuspended in 100 µl of FACS buffer (PBS supplemented with 0.2% BSA (Sigma-Aldrich)) containing mouse specific cell surface markers for flow cytometry. Markers included anti-mouse CD44 PerCP-Cy5.5 and CD4 APC/Fire750⁷². Details of the clone and manufacturer of each marker used in a customized six colors flow-cytometry panel are documented in Supplementary Fig. 3C. Cells were incubated with the surface markers for 30 min at 4°C. Cells were washed with PBS and fixed/permeabilized by using the BD Cytofix/Cytoperm fixation/permeabilization solution kit according to the manufacturer's instructions. Cells were washed in 1X perm/wash solution and subjected to intracellular staining (30 min at 4°C) using a cocktail of the following Abs: anti-mouse IFN γ Alexa Fluor 488, IL-4/5 BV421 and IL-17A Alexa Fluor 647 in 1X perm/wash solution. Finally, cells were washed in PBS and fixed in PBS containing 1% paraformaldehyde (Electron Microscopy Sciences, Hatfield, PA) for 20 min at 4°C. After two final washes in PBS, the cells were resuspended in PBS and stored at 4°C until acquisition. Samples were acquired on a BD LSR II (BD Biosciences; San Jose, CA) configured with blue (488 nm), yellow/green (561 nm), red (640 nm), violet (405 nm), and ultraviolet (355 nm) lasers using standardized good clinical laboratory practice procedures to minimize variability of data generated. Analysis was performed using FlowJo software, v.10.7.1 according to the gating strategy outlined in Supplementary Fig. 3A, B.

Human Monocyte Derived Dendritic Cells (MoDC) assay. Monocytes were isolated from PBMC and CBMC fractions through positive selection by magnetic microbeads according to the manufacturer's instructions (Miltenyi Biotec, Auburn, CA) using CD14 as a pan marker. Isolated monocytes were cultured in tissue culture dishes at 10⁶ cells/ml in RPMI 1640 media containing fresh 10% autologous plasma, supplemented with recombinant human IL-4 (50 ng/ml) and recombinant human GM-CSF (100 ng/ml) (R&D Systems, Minneapolis, MN) with one additional supplement of fresh media and cytokines at day 3 of culture as previously described^{26,73}. After 6 days, immature MoDCs were harvested by gently pipetting the loosely adherent fraction, before being re-plated (10⁵ cells/ well) in 96-well U-bottom plates in the presence or absence of TLRs, and/or 2% Glycerol, and/or sterile PBS. Plates were then incubated for 18–

24 h at 37°C in a humidified incubator at 5% CO₂. After this stimulation supernatants were harvested and processed for further functional assays.

Statistical analyses and graphics. Statistical significance and graphic output were generated using GraphPad Prism version 9 for macOS (GraphPad Software, La Jolla, CA, USA). Data were tested for normality by using the Shapiro-Wilk test. Group comparisons were performed by One-way ANOVA with Dunnett's multiple comparison post-test or Two-way ANOVA comparing column and row effects. Measurements that failed normality tests were analyzed with Wilcoxon rank-sum tests or a Kruskal-Wallis rank-sum test comparisons within treatments groups. Results were considered significant at *p* values indicated in each figure legend. Graphics in Fig. 3B, Fig. 4A, Fig. 6A, Fig. S1A, Fig. S2A and Fig. S6A were created with BioRender.com.

Declarations

Acknowledgments

The authors would like to acknowledge GlaxoSmithKline's research license for UM-300X compounds use. This work was supported in part by the National Institute of Allergy and Infectious Diseases (NIAID) under Adjuvant Discovery contract HHSN272200900036C (to University of Montana) and by the Center for Translational Medicine at University of UM. Work performed in O.L.'s laboratory was supported by Adjuvant Discovery (75N93019C00044), and Development (272201800047C), and an internal Boston Children's Hospital award to the *Precision Vaccines Program*. D.J.D.'s laboratory was supported by NIH grant 5R21AI137932-02 and Adjuvant Discovery Program (75N93019C00044). We thank the members of the *Precision Vaccines Program* for assistance with phlebotomy as well as helpful discussions. We thank our donors and acknowledge the assistance of the Labor and Delivery staff at both The Brigham & Women's Hospital, Boston and Beth Israel Deaconess Medical Center, Boston. We are grateful for the mentorship and support of Dr. Gary R. Fleisher and David A. Williams. F.B. was supported by UniNA and Compagnia di San Paolo, in the frame of Programme STAR.

Author contributions

D.J.D., S.B., A.J.S., H.G.B., O.L. and J.T.E. conceptualized, designed the experiments and wrote the manuscript. A.J.S., S.B., F.B., D.C., S.E.B., G.M., B.B., M.M., D.S., S.S., K.S., and E.N performed the experiments. D.J.D., A.J.S., S.B., F.B., S.E.B., G.M., M.M., D.S., S.S., K.S. and H.G.B analyzed and interpreted the data and all authors reviewed the manuscript.

Data availability

The datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request.

Competing Interests

D.J.D., O.L., D.B., H.G.B., F.B. and J.T.E. are named inventors on several patent applications related to vaccine adjuvants. J.T.E., D.B. and H.G.B. are employees and co-founders of Inimmune Corporation. F.B. has signed consulting agreements with Merck Sharp & Dohme Corp. (a subsidiary of Merck & Co., Inc.), Sana Biotechnology, Inc., and F. Hoffmann-La Roche Ltd. These commercial relationships are unrelated to the current study.

References

- 1 Cherry, J. D. Treatment of Pertussis-2017. *Journal of the Pediatric Infectious Diseases Society*, doi:10.1093/jpids/pix044 (2017).
- 2 Mattoo, S. & Cherry, J. D. Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to *Bordetella pertussis* and other *Bordetella* subspecies. *Clinical microbiology reviews* **18**, 326-382, doi:10.1128/cmr.18.2.326-382.2005 (2005).
- 3 Tan, T., Trindade, E. & Skowronski, D. Epidemiology of pertussis. *The Pediatric infectious disease journal* **24**, S10-18 (2005).
- 4 Burdin, N., Handy, L. K. & Plotkin, S. A. What Is Wrong with Pertussis Vaccine Immunity? The Problem of Waning Effectiveness of Pertussis Vaccines. *Cold Spring Harbor perspectives in biology* **9**, doi:10.1101/cshperspect.a029454 (2017).
- 5 Gu, X. X. *et al.* Waning Immunity and Microbial Vaccines-Workshop of the National Institute of Allergy and Infectious Diseases. *Clinical and vaccine immunology : CVI* **24**, doi:10.1128/cvi.00034-17 (2017).
- 6 Le, T. *et al.* Immune responses and antibody decay after immunization of adolescents and adults with an acellular pertussis vaccine: the APERT Study. *J Infect Dis* **190**, 535-544, doi:10.1086/422035 (2004).
- 7 Heininger, U., Cherry, J. D. & Stehr, K. Serologic response and antibody-titer decay in adults with pertussis. *Clin Infect Dis* **38**, 591-594, doi:10.1086/381439 (2004).
- 8 Fouda, G. G., Martinez, D. R., Swamy, G. K. & Permar, S. R. The Impact of IgG transplacental transfer on early life immunity. *Immunohorizons* **2**, 14-25, doi:10.4049/immunohorizons.1700057 (2018).
- 9 Skoff, T. H., Baumbach, J. & Cieslak, P. R. Tracking Pertussis and Evaluating Control Measures through Enhanced Pertussis Surveillance, Emerging Infections Program, United States. *Emerging infectious diseases* **21**, 1568-1573, doi:10.3201/eid2109.150023 (2015).
- 10 Poolman, J. T. Shortcomings of pertussis vaccines: why we need a third generation vaccine. *Expert review of vaccines* **13**, 1159-1162, doi:10.1586/14760584.2014.944902 (2014).

- 11 Dowling, D. J. & Levy, O. Pediatric vaccine adjuvants: Components of the modern vaccinologist's toolbox. *The Pediatric infectious disease journal*, doi:10.1097/inf.0000000000000893 (2015).
- 12 Dowling, D. J. & Levy, O. Ontogeny of early life immunity. *Trends Immunol* **35**, 299-310, doi:10.1016/j.it.2014.04.007 (2014).
- 13 Pollard, A. J., Perrett, K. P. & Beverley, P. C. Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. *Nat Rev Immunol* **9**, 213-220, doi:nri2494 [pii] 10.1038/nri2494 [doi] (2009).
- 14 Queenan, A. M. *et al.* Increasing FIM2/3 antigen-content improves efficacy of Bordetella pertussis vaccines in mice in vivo without altering vaccine-induced human reactogenicity biomarkers in vitro. *Vaccine* **37**, 80-89, doi:10.1016/j.vaccine.2018.11.028 (2019).
- 15 Allen, A. C. & Mills, K. H. Improved pertussis vaccines based on adjuvants that induce cell-mediated immunity. *Expert review of vaccines* **13**, 1253-1264, doi:10.1586/14760584.2014.936391 (2014).
- 16 Dowling, D. J. & Levy, O. Pediatric Vaccine Adjuvants: Components of the Modern Vaccinologist's Toolbox. *Pediatr Infect Dis J* **34**, 1395-1398, doi:10.1097/INF.0000000000000893 (2015).
- 17 Nanishi, E., Dowling, D. J. & Levy, O. Toward precision adjuvants: optimizing science and safety. *Curr Opin Pediatr* **32**, 125-138, doi:10.1097/MOP.0000000000000868 (2020).
- 18 Soni, D. *et al.* Towards Precision Vaccines: Lessons From the Second International Precision Vaccines Conference. *Frontiers in immunology* **11**, doi:10.3389/fimmu.2020.590373 (2020).
- 19 van Haren, S. D. *et al.* In vitro cytokine induction by TLR-activating vaccine adjuvants in human blood varies by age and adjuvant. *Cytokine* **83**, 99-109, doi:10.1016/j.cyto.2016.04.001 (2016).
- 20 Reed, S. G., Orr, M. T. & Fox, C. B. Key roles of adjuvants in modern vaccines. *Nat Med* **19**, 1597-1608, doi:nm.3409 [pii] 10.1038/nm.3409 [doi] (2013).
- 21 Philbin, V. J. *et al.* Imidazoquinoline Toll-like receptor 8 agonists activate human newborn monocytes and dendritic cells through adenosine-refractory and caspase-1-dependent pathways. *J Allergy Clin Immunol* **130**, 195-204 e199, doi:10.1016/j.jaci.2012.02.042 (2012).
- 22 Ugolini, M. *et al.* Recognition of microbial viability via TLR8 drives TFH cell differentiation and vaccine responses. *Nat Immunol* **19**, 386-396, doi:10.1038/s41590-018-0068-4 (2018).
- 23 Browne, E. P. Regulation of B-cell responses by Toll-like receptors. *Immunology* **136**, 370-379, doi:10.1111/j.1365-2567.2012.03587.x (2012).

- 24 Levy, O. *et al.* The adenosine system selectively inhibits TLR-mediated TNF-alpha production in the human newborn. *J Immunol* **177**, 1956-1966, doi:10.4049/jimmunol.177.3.1956 (2006).
- 25 Dowling, D. J. *et al.* The ultra-potent and selective TLR8 agonist VTX-294 activates human newborn and adult leukocytes. *PLoS One* **8**, e58164, doi:10.1371/journal.pone.0058164 (2013).
- 26 Dowling, D. J. *et al.* Toll-like receptor 8 agonist nanoparticles mimic immunomodulating effects of the live BCG vaccine and enhance neonatal innate and adaptive immune responses. *J Allergy Clin Immunol* **140**, 1339-1350, doi:10.1016/j.jaci.2016.12.985 (2017).
- 27 Holbrook, B. C. *et al.* An R848 adjuvanted influenza vaccine promotes early activation of B cells in the draining lymph nodes of non-human primate neonates. *Immunology*, doi:10.1111/imm.12845 (2017).
- 28 Dowling, D. J. *et al.* TLR7/8 adjuvant overcomes newborn hyporesponsiveness to pneumococcal conjugate vaccine at birth. **2**, e91020, doi:10.1172/jci.insight.91020 (2017).
- 29 Pettengill, M. A. *et al.* Distinct TLR-mediated cytokine production and immunoglobulin secretion in human newborn naive B cells. *Innate immunity*, doi:10.1177/1753425916651985 (2016).
- 30 Misiak, A. *et al.* Addition of a TLR7 agonist to an acellular pertussis vaccine enhances Th1 and Th17 responses and protective immunity in a mouse model. *Vaccine* **35**, 5256-5263, doi:10.1016/j.vaccine.2017.08.009 (2017).
- 31 Soni, D., Bobbala, S., Li, S., Scott, E. A. & Dowling, D. J. The sixth revolution in pediatric vaccinology: immunoengineering and delivery systems. *Pediatr Res*, 1-9, doi:10.1038/s41390-020-01112-y (2020).
- 32 Brito, L. A., Malyala, P. & O'Hagan, D. T. Vaccine adjuvant formulations: A pharmaceutical perspective. *Semin Immunol* **25**, 130-145, doi:S1044-5323(13)00037-7 [pii] 10.1016/j.smim.2013.05.007 [doi] (2013).
- 33 Dowling, D. J. Recent Advances in the Discovery and Delivery of TLR7/8 Agonists as Vaccine Adjuvants. *Immunohorizons* **2**, 185-197, doi:10.4049/immunohorizons.1700063 (2018).
- 34 Vasilakos, J. P. & Tomai, M. A. The use of Toll-like receptor 7/8 agonists as vaccine adjuvants. *Expert review of vaccines* **12**, 809-819, doi:10.1586/14760584.2013.811208 [doi] (2013).
- 35 Sauder, D. N., Smith, M. H., Senta-McMillian, T., Soria, I. & Meng, T. C. Randomized, single-blind, placebo-controlled study of topical application of the immune response modulator resiquimod in healthy adults. *Antimicrobial agents and chemotherapy* **47**, 3846-3852 (2003).
- 36 Szeimies, R. M. *et al.* A phase II dose-ranging study of topical resiquimod to treat actinic keratosis. *The British journal of dermatology* **159**, 205-210, doi:10.1111/j.1365-2133.2008.08615.x (2008).

- 37 Dowling, D. J. *et al.* TLR7/8 adjuvant overcomes newborn hyporesponsiveness to pneumococcal conjugate vaccine at birth. *JCI Insight* **2**, e91020, doi:10.1172/jci.insight.91020 (2017).
- 38 Kasturi, S. P. *et al.* 3M-052, a synthetic TLR-7/8 agonist, induces durable HIV-1 envelope-specific plasma cells and humoral immunity in nonhuman primates. *Sci Immunol* **5**, doi:10.1126/sciimmunol.abb1025 (2020).
- 39 Smith, A. J. *et al.* Evaluation of novel synthetic TLR7/8 agonists as vaccine adjuvants. *Vaccine* **34**, 4304-4312, doi:10.1016/j.vaccine.2016.06.080 (2016).
- 40 Gerster, J. F. *et al.* Synthesis and structure-activity-relationships of 1H-imidazo[4,5-c]quinolines that induce interferon production. *Journal of medicinal chemistry* **48**, 3481-3491, doi:10.1021/jm049211v (2005).
- 41 Evans, J. T. *et al.* Synthetic Toll-like Receptors 7 and 8 Agonists: Structure-Activity Relationship in the Oxoadenine Series. *ACS Omega* **4**, 15665-15677, doi:10.1021/acsomega.9b02138 (2019).
- 42 Bazin, H. G. *et al.* Optimization of 8-oxoadenines with toll-like-receptor 7 and 8 activity. *Bioorg Med Chem Lett* **30**, 126984, doi:10.1016/j.bmcl.2020.126984 (2020).
- 43 Pettengill, M. A., van Haren, S. D. & Levy, O. Soluble mediators regulating immunity in early life. *Frontiers in immunology* **5**, 457, doi:10.3389/fimmu.2014.00457 (2014).
- 44 Mastelic, B. *et al.* Predictive markers of safety and immunogenicity of adjuvanted vaccines. *Biologicals : journal of the International Association of Biological Standardization* **41**, 458-468, doi:10.1016/j.biologicals.2013.08.006 (2013).
- 45 Horscroft, N. J., Pryde, D. C. & Bright, H. Antiviral applications of Toll-like receptor agonists. *The Journal of antimicrobial chemotherapy* **67**, 789-801, doi:10.1093/jac/dkr588 (2012).
- 46 Strominger, N. L., Brady, R., Gullikson, G. & Carpenter, D. O. Imiquimod-elicited emesis is mediated by the area postrema, but not by direct neuronal activation. *Brain Research Bulletin* **55**, 445-451, doi:[https://doi.org/10.1016/S0361-9230\(01\)00539-1](https://doi.org/10.1016/S0361-9230(01)00539-1) (2001).
- 47 Lee, J. *et al.* Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: activation of Toll-like receptor 7. *Proceedings of the National Academy of Sciences of the United States of America* **100**, 6646-6651, doi:10.1073/pnas.0631696100 (2003).
- 48 Chan, M. *et al.* Synthesis and Immunological Characterization of Toll-Like Receptor 7 Agonistic Conjugates. *Bioconjugate Chemistry* **20**, 1194-1200, doi:10.1021/bc900054q (2009).
- 49 Bazin, H. G., Bess, L. S., Livesay, M. T., Mwakwari, S. C. & Johnson, D. A. Phospholipidation of TLR7/8-active imidazoquinolines using a tandem phosphoramidite method. *Tetrahedron Letters* **57**, 2063-2066, doi:10.1016/j.tetlet.2016.03.091 (2016).

- 50 Bazin, H. G. a. J., D. A. Pegylated Imidazoquinolines as TLR7 and TLR8 Agonists. (2017).
- 51 HogenEsch, H., O'Hagan, D. T. & Fox, C. B. Optimizing the utilization of aluminum adjuvants in vaccines: you might just get what you want. *NPJ Vaccines* **3**, 51, doi:10.1038/s41541-018-0089-x (2018).
- 52 Bruschi, M. L. *Strategies to modify the drug release from pharmaceutical systems*. 1st edition. edn, (Elsevier, 2015).
- 53 Borriello, F. *et al.* Identification and Characterization of Stimulator of Interferon Genes As a Robust Adjuvant Target for Early Life Immunization. *Front Immunol* **8**, 1772, doi:10.3389/fimmu.2017.01772 (2017).
- 54 Collier, M. A. *et al.* Acetalated Dextran Microparticles for Codelivery of STING and TLR7/8 Agonists. *Mol Pharm* **15**, 4933-4946, doi:10.1021/acs.molpharmaceut.8b00579 (2018).
- 55 Libster, R. & Edwards, K. M. Re-emergence of pertussis: what are the solutions? *Expert review of vaccines* **11**, 1331-1346, doi:10.1586/erv.12.118 (2012).
- 56 Martinon-Torres, F., Heininger, U., Thomson, A. & Wirsing von Konig, C. H. Controlling pertussis: how can we do it? A focus on immunization. *Expert review of vaccines* **17**, 289-297, doi:10.1080/14760584.2018.1445530 (2018).
- 57 Liu, L. *et al.* Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000. *Lancet* **379**, 2151-2161, doi:S0140-6736(12)60560-1 [pii] 10.1016/S0140-6736(12)60560-1 [doi] (2012).
- 58 Wu, T. Y. *et al.* Rational design of small molecules as vaccine adjuvants. *Sci Transl Med* **6**, 263ra160, doi:10.1126/scitranslmed.3009980 (2014).
- 59 Miller, S. M. *et al.* Novel Lipidated Imidazoquinoline TLR7/8 Adjuvants Elicit Influenza-Specific Th1 Immune Responses and Protect Against Heterologous H3N2 Influenza Challenge in Mice. *Frontiers in immunology* **11**, 406, doi:10.3389/fimmu.2020.00406 (2020).
- 60 Koff, W. C. *et al.* Accelerating next-generation vaccine development for global disease prevention. *Science (New York, N.Y.)* **340**, 1232910, doi:10.1126/science.1232910 (2013).
- 61 Delany, I., Rappuoli, R. & De Gregorio, E. Vaccines for the 21st century. *EMBO molecular medicine* **6**, 708-720, doi:10.1002/emmm.201403876 (2014).
- 62 Cortez, A. *et al.* Incorporation of Phosphonate into Benzonaphthyridine Toll-like Receptor 7 Agonists for Adsorption to Aluminum Hydroxide. *Journal of medicinal chemistry* **59**, 5868-5878, doi:10.1021/acs.jmedchem.6b00489 (2016).

- 63 Buonsanti, C. *et al.* Novel adjuvant Alum-TLR7 significantly potentiates immune response to glycoconjugate vaccines. *Scientific reports* **6**, 29063, doi:10.1038/srep29063 (2016).
- 64 Gonzalez-Lopez, A. *et al.* Adjuvant effect of TLR7 agonist adsorbed on aluminum hydroxide (AS37): A phase I randomized, dose escalation study of an AS37-adjuvanted meningococcal C conjugated vaccine. *Clin Immunol* **209**, 108275, doi:10.1016/j.clim.2019.108275 (2019).
- 65 Jangra, S. *et al.* Sterilizing Immunity against SARS-CoV-2 Infection in Mice by a Single-Shot and Lipid Amphiphile Imidazoquinoline TLR7/8 Agonist-Adjuvanted Recombinant Spike Protein Vaccine*. *Angew Chem Int Ed Engl* **60**, 9467-9473, doi:10.1002/anie.202015362 (2021).
- 66 Mills, K. H., Ross, P. J., Allen, A. C. & Wilk, M. M. Do we need a new vaccine to control the re-emergence of pertussis? *Trends Microbiol* **22**, 49-52, doi:10.1016/j.tim.2013.11.007 (2014).
- 67 Kapil, P. & Merkel, T. J. Pertussis vaccines and protective immunity. *Current opinion in immunology* **59**, 72-78, doi:10.1016/j.coi.2019.03.006 (2019).
- 68 Warfel, J. M., Zimmerman, L. I. & Merkel, T. J. Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model. *Proceedings of the National Academy of Sciences of the United States of America* **111**, 787-792, doi:10.1073/pnas.1314688110 (2014).
- 69 Kuijpers, A. J. *et al.* In vivo and in vitro release of lysozyme from cross-linked gelatin hydrogels: a model system for the delivery of antibacterial proteins from prosthetic heart valves. *J Control Release* **67**, 323-336, doi:10.1016/s0168-3659(00)00221-2 (2000).
- 70 Northrup, L. *et al.* Co-delivery of autoantigen and dexamethasone in incomplete Freund's adjuvant ameliorates experimental autoimmune encephalomyelitis. *J Control Release* **266**, 156-165, doi:10.1016/j.jconrel.2017.09.034 (2017).
- 71 Zhang, Y. *et al.* DDSolver: an add-in program for modeling and comparison of drug dissolution profiles. *AAPS J* **12**, 263-271, doi:10.1208/s12248-010-9185-1 (2010).
- 72 Raeven, R. H. M. *et al.* Molecular and cellular signatures underlying superior immunity against *Bordetella pertussis* upon pulmonary vaccination. *Mucosal Immunol* **11**, 1009, doi:10.1038/mi.2017.110 (2018).
- 73 Ganapathi, L. *et al.* The Imidazoquinoline Toll-Like Receptor-7/8 Agonist Hybrid-2 Potently Induces Cytokine Production by Human Newborn and Adult Leukocytes. *PLoS One* **10**, e0134640, doi:10.1371/journal.pone.0134640 (2015).
- 74 Smith, A. J. *et al.* Evaluation of novel synthetic TLR7/8 agonists as vaccine adjuvants. *Vaccine* **34**, 4304-4312, doi:<http://dx.doi.org/10.1016/j.vaccine.2016.06.080> (2016).

75 Bazin, H. G. *et al.* Structural requirements for TLR7-selective signaling by 9-(4-piperidinylalkyl)-8-oxoadenine derivatives. *Bioorganic & Medicinal Chemistry Letters* **25**, 1318-1323, doi:<http://dx.doi.org/10.1016/j.bmcl.2015.01.037> (2015).

Table 1

Table 1 is available in the Supplementary Files section.

Supporting Information Captions

Fig. S1. Imidazoquinoline UM-3001 induces IFN γ production in neonatal CBMCs. (A) Graphical representation of newborn CBMCs were stimulated with either UM-3009 or UM-3001, in the presence of the polyclonal T cell activator α CD3 (5 mg/ml) for 96 h. IFN γ levels were measured in cell-free supernatants by ELISA. (B) Results are depicted as the median, the 25th and 75th percentiles (boxes) and the 5th and 95th percentiles (whiskers) of 10 independent experiments. Statistical analysis employed one-way ANOVA followed; * $p < 0.033$.

Fig. S2. UM-3003 enhances DTaP induced Ab production in adult mice in a titratable manner. Adult BALB/c mice were immunized twice, 14 days apart (A) with DTaP (1/100th of the human dose) \pm UM-3001 or UM-3003 at 0.1 μ g, 1 μ g or 10 μ g per mouse in different formulations (aqueous or pre-adsorbed to alum). Serum was harvested 14 days following prime (B-C) or boost (D-E) and anti-FHA serum Ab IgG1 and IgG2a titers were measured by ELISA. Saline control groups were below the lowest limit of detection. Dotted line represented DTaP immunized group. Statistical comparison employed test one-way ANOVA; * $p < 0.033$, ** $p < 0.002$, *** $p < 0.001$ ($n = 6 - 10$ per group), with comparison to *Infanrix* alone. Study is representative of two separate repeats.

Fig. S3. Gating strategy to identify FHA- and PRN-specific CD4⁺ T cells. Splenocytes were isolated from immunized mice following four weeks booster. Antigen-specific T cell responses following FHA/PRN stimulation were defined as CD44^{hi}/CD4^{hi}/cytokine⁺ using FlowJo software, v.10.7.1. (A) Shown is an example of the hierarchical gating strategy leading to the identification of live, singlet, CD44⁺, CD4⁺ and cytokine⁺ T cells (B) with an example for IFN γ , IL-4/5 and IL-17 response post vaccination with DTaP \pm UM-3003. (C) Reagents for Flow Cytometric Analysis. Murine CD4⁺ T cell compartment was dissected by a customized six colors flow-cytometry panel.

Fig. S4. UM-3003 enhances DTaP specific IFN γ recall responses in adult and infant mice. Splenocytes were isolated from immunized adult (A-F) or infant (G-L) C57BL/6 mice following four weeks booster and stimulated with 2 mg/ml of either FHA or PRN along with CD28 (1 mg/ml) and CD49d (1 mg/ml) for 72 - 80 h. After stimulation, supernatants were collected for multiplex assay. FHA specific IFN γ (A, G), IL-17 (B, H) responses (pg/ml) and PRN specific IFN γ (D, J) along with IL-17 (E, K) responses (pg/ml) were represented ($n = 8-15$ for adult and 5-11 for infant mice). (C, F, I, L) Data are shown as fold change for adjuvanted group over DTaP immunized group (red line). For comparisons between overall groups,

ordinary one-way ANOVA was applied, and statistical significance denoted as $*p < 0.033$, $**p < 0.002$ and $***p < 0.001$.

Fig. S5. UM-3001 and UM-3003 demonstrate concentration-dependent cytokine potency in newborn and adult human MoDCs. Newborn (n = 4 - 5) and adult (n = 6) MoDCs were stimulated for 24h and supernatants were collected for multiplex assay. Cytokine responses of 13 analytes were represented as a radar plot. TLR4 agonist LPS (100 ng/ml), TLR7/8 agonists R848 and CL075 were employed as benchmarks. 2% glycerin in PBS served as a vehicle control.

Fig. S6. Formulation of UM-3001 with the DTaP did not enhance Ab production in neonatal mice. (A) 7 days old C57BL/6, 4 - 5 per group, were vaccinated (prime/ boost) with DTaP (1/100th of the human dose), ± UM-3001 at 1 µg or 10 µg per mouse. Serum was harvested 14 days following boost (14dp2) (DOL 28) and (B) anti-FHA serum total IgG titers, IgG1 and IgG2c were measured by ELISA. Dotted line represented DTaP immunized group. Statistical comparison employed test by one-way ANOVA with comparison to DTaP alone.

Table S1. Cytokine profiling in human newborn cord blood after imidazoquinoline UM-3001 stimulation. (A) Data are shown as mean value of cytokine responses (pg/ml) for stimulated newborn cord or adult whole blood by 1 µM and 10 µM of UM-3001, (n = 6 adults, n = 8 newborn). Newborn and adult blood were cultured separately *in vitro* for 6 h with UM-3001. Supernatants were collected for multiplex assay. All significance determined by unpaired two-sided Wilcoxon rank-sum test where $*P < 0.033$ and $**P < 0.002$.

Table S2. Core compound UM-3001 does not absorb to the alum/antigen. Direct adsorption of UM-3001 to aluminum hydroxide derived from DTaP (*Infanrix*) vaccine, which has pertussis antigen adsorbed to its surface, was evaluated at 1, 2 and 24 hrs. The core UM-3001 compound demonstrated only minimal adsorption to the antigen (~ 4 - 7 % within 1-2 hr), with peak area intensity levels similar to the unmixed controls, mAU: milli-absorbance units.

Table S3. Cytokine profiling in human newborn MoDCs and CBMC after lipidated imidazoquinoline UM-3003 stimulation. (A, B) Newborn MoDCs were stimulated for 24 h and supernatants were collected for multiplex assay. Data are shown as mean value of cytokine responses (pg/ml) of 13 analytes (n = 5). (C, D) CBMCs were stimulated in the presence of the polyclonal T cell activators α-CD3 (5 µg/ml) in combination or alone for 96 h. TLR7/8 agonist CL075 (10 µM) and STING agonist 2'3'-cGAMP (10 µM) in combination were used as a benchmark control. Data are shown as mean value of cytokine responses (pg/ml) of 5 analytes (n = 6). Statistical analysis employed one-way ANOVA followed by Kruskal-Wallis multiple comparisons test; $*p < 0.033$ and $**P < 0.002$.

Figures

Figure 1




Figure 1

Overview of the core-aqueous imidazoquinoline and oxoadenine scaffolds. (A) Naming convention, chemical class and TLR selectivity of each core scaffolds^{59,74,75}; (B) core imidazoquinolines; and core oxoadenines investigated in this study. (C-D) Six TLR agonists were compared. HEK-293 cells transfected with (C) human TLR7 or (D) human TLR8 and an NF-κB-driven reporter SEAP gene were stimulated for 18–24 h with TLR agonists. The y-axis shows the level of SEAP activity as a fold change over unstimulated cells. The x-axis shows the concentration of each compound in μM. Each data point represents the mean of triplicate culture wells, and representative of three separate experiments. (E) Amongst the IMQ and OA compounds evaluated in a HEK293 assay, UM-3001 was the most potent for both TLR7 and TLR8, with a preference for TLR8.

Figure 2




Figure 2

Imidazoquinoline UM-3001 demonstrated age-specific potency, effectiveness and IFN γ production in human newborn cord blood. (A-B) Human neonatal cord blood cultured *in vitro* for 6 h with buffer control (RPMI) or with increasing concentrations of various UM adjuvants. (C-D) Newborn versus adult blood cultured *in vitro* for 6 h with UM-3001. Supernatants were collected for ELISA. Results represent means \pm SEM, A-B; n = 7, (C-D); n = 7. Cell supernatants were analyzed for cytokine expression by multiplex assay. Data are shown as fold change for newborn cord (blue line) over adult stimulated whole blood (black

line) for 1 μM (E) and 10 μM (F) UM-3001. ($n = 6$ adults, $n = 8$ newborn). For comparisons between overall groups (e.g., newborn vs. adult), two-way repeated measures ANOVA was applied, and statistical significance denoted as $*p < 0.033$.

Figure 3




Figure 3

The optimized phospholipidated TLR7/8 agonist UM-3003 rapidly and fully adsorbed onto alum. (A) Chemical structure of the lead TLR7/8 agonist UM-3003. The phosphorylated derivative of the IMQ UM-3001 was modified through introduction of a polyethylene glycol (PEG) linker of 3 repeating units generating a compound that was named UM-3003. (B) *In vitro* release and desorption profile of UM-3003 from UM-3003 alhydrogel adsorbed formulation in adjuvant free human plasma. Percentage desorption are divided by the maximum to scale from 0 to 100. (C) Average particle size, pH and polydispersity index of UM-3003 in 2% glycerol.

ratios for FHA and PRN respectively. (J, K) Murine CD4⁺ T cell responses after FHA and PRN stimulation. Four weeks following booster, splenocytes from DTaP and adjuvanted vaccinates were isolated, stimulated with 2 mg/ml of either FHA or PRN along with CD28 (1 mg/ml) and CD49d (1 mg/ml) for 12 h followed by 6 h of BFA stimulation to block the extracellular cytokine secretion. After stimulation, cells were harvested, stained (intracellular cytokine staining) and analyzed by flow cytometry. Plots were gated on CD44⁺ CD4⁺ lymphocytes and analyzed for all combinations of simultaneous IFN γ , IL-4/5 and IL-17A productivity. Statistical comparison employed test one-way ANOVA; * p < 0.033, ** p < 0.002, *** p < 0.001 (n = 8 - 15 per group), with comparison to DTaPalone. Study is inclusive of three independent repeats.

Figure 5




Figure 5

Lipidated imidazoquinoline UM-3003 demonstrates robust potency and efficacy in inducing Th-polarizing cytokines from human newborn MoDCs. (A-B) Newborn MoDCs were stimulated for 24 h and supernatants were collected for multiplex assay. Cytokine responses (pg/ml) of 13 analytes (n = 5) were represented in radar plot (A) demonstrating neonatal MoDCs concurrently stimulated in the presence of 2% glycerin (vehicle control) or 100 ng/ml of LPS or 10 μ M of UM-3003. (B) Fold-change of 100 ng/ml of

LPS or 10 μ M of UM-3003 over vehicle control are shown. (C) TNF (n = 5), (D) IL-12p70 (n = 5) ELISA were performed by stimulated supernatants where lipidated compound demonstrating similar TNF induction ability compared with LPS, but slightly increased IL-12p70 production. In, (E-F), cord blood mononuclear cells (CBMCs) (n = 6) were stimulated in the presence of the polyclonal T cell activators α -CD3 (5 μ g/ml) in combination or alone for 96 h. TLR7/8 agonist (CL075, 10 μ M) and STING agonist (2'3'-cGAMP, 10 μ M) in combination were used as a benchmark control. (E) Radar plot demonstrated total cytokine levels (pg/ml) in cell free supernatants by a high sensitivity T cell multiplex assay from six independent experiments. (F) Fold changes relative to vehicle control are shown. Statistical analysis employed one-way ANOVA and statistical significance denoted as * p < 0.033, ** p < 0.001.

Figure 6




Figure 6

UM-3003 enhances DTaP specific IgG2c production and Th1/Th17 polarization in neonatal mice. (A) 7 days old C57BL/6 were vaccinated (prime/ boost) with DTaP (1/100th of the human dose), \pm UM-3003 or UM-3003 at 10 μ g per mouse in alum absorbed formulations. Serum was harvested 14 days following boost (DOL 28). Anti-FHA (B-E) and anti-PRN (F-I) serum total IgG titers, IgG1 and IgG2c were measured by ELISA. PBS control groups were represented as dotted line. (E, I) IgG2c/IgG1 ratios for FHA and PRN

respectively. (J, K) Splenic CD4⁺ T cell responses after FHA and PRN stimulation. Four weeks following booster, splenocytes from vaccinates were isolated and stimulated with 2 mg/ml of either FHA or PRN along with CD28 (1 mg/ml) and CD49d (1 mg/ml) for 12 h followed by 6 h of BFA stimulation. After stimulation, cells were harvested and stained (intracellular cytokine staining) and analyzed by flow cytometry. Plots were gated on CD44⁺ CD4⁺ lymphocytes and analyzed for all combinations of simultaneous IFN γ , IL-4/5 and IL-17A productivity. (L) Fold change of FHA specific IFN γ production in splenic CD4⁺ T cell relative to DTaP are shown. Statistical comparison employed test one-way ANOVA; * $p < 0.033$, ** $p < 0.002$, *** $p < 0.001$ ($n = 9 - 13$ per group), with comparison to DTaP alone. Study is inclusive of two independent repeats.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [Table1.pdf](#)
- [CombinedSupplement.pdf](#)